Lucerastat

DB14872InvestigationalSmall molecule

Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).

Mechanism: Pharmacologically active on Ceramide glucosyltransferase
Curator reviewed
Formula / weight: C₁₀H₂₁NO₄ · 219.281 g/mol (avg)

Resolves to

Compound

UNIIGVS3YDM418CAS141206-42-0ChEMBLCHEMBL1086997

Structure

InChIKeyUQRORFVVSGFNRO-XFWSIPNHSA-NSMILESCCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO

Targets

Q16739UGCG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lucerastat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account